Drug rebates paid between pharmaceutical companies and pharmacy benefit managers enjoy safe harbor status under federal kickback law, leaving them immune from legal scrutiny. But that could change, FDA chief Dr. Scott Gottlieb suggested yesterday at the FDA Law Institute’s annual meeting.
The commissioner reportedly hinted that reinterpreting the law could help lower drug prices.
Get the full story at our sister site, Drug Delivery News.
The post FDA chief suggests kickback laws could be used to rein in drug prices appeared first on MassDevice.
from MassDevice https://ift.tt/2wcdimf
Cap comentari:
Publica un comentari a l'entrada